← FDA DRUG APPROVALS

FDA ANDA · ANDA203133

DEXTROMETHORPHAN POLISTIREX EXTENDED-RELEASE

dextromethorphan polistirex

Sponsor: AMNEAL

APPLICATION
ANDA203133
TYPE
ANDA
ORIGINAL APPROVAL
2017-07-28
LATEST ACTION
2017-07-28
ROUTE
ORAL
DOSAGE FORM
SUSPENSION, EXTENDED RELEASE
MARKETING STATUS
Over-the-counter

Products

DEXTROMETHORPHAN POLISTIREXOver-the-counter
DEXTROMETHORPHAN POLISTIREX EQ 30MG HYDROBROMIDE/5ML · SUSPENSION, EXTENDED RELEASE · ORAL

Approval history

2017-07-28UNKNOWN · Original — Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →